The Remarkable Turnaround: Opioid Toxicity Deaths Dropping Across Canada
Canada has witnessed a significant shift in its long-standing battle against the opioid crisis. After years of heartbreaking increases, opioid-related deaths have begun to decline sharply. Public health data reveals a national drop of 17 percent in apparent opioid toxicity deaths in 2024 compared to 2023, with the trend continuing into 2025. From January to June 2025, the overdose death rate fell to 13.5 per 100,000 people, down from a peak of 20 per 100,000. This represents at least a one-third reduction over the past two years, offering a glimmer of hope amid over 53,300 cumulative deaths since 2016, largely fueled by illicit fentanyl.
These improvements are not uniform, with the steepest declines in provinces like British Columbia, Alberta, Saskatchewan, Ontario, Manitoba, New Brunswick, and Yukon. For instance, Alberta saw a 37 percent decrease, from 1,873 deaths in 2023 to 1,185 in 2024. Conversely, Quebec and Newfoundland and Labrador experienced increases of 20 percent and 22 percent, respectively, highlighting regional disparities. Despite the progress, rates remain elevated compared to pre-2019 levels, underscoring the need for sustained vigilance.
This decline coincides with evolving research from Canadian universities and public health agencies, providing evidence-based insights into the drivers. Institutions like the University of Waterloo and Dalhousie University have contributed key studies on prescribing patterns and regional mortality trends, informing national responses.
National and Provincial Statistics: Painting the Picture of Progress
The Public Health Agency of Canada (PHAC) tracks these trends meticulously through its Substance-Related Harms dashboard. In the first half of 2025, 2,787 apparent opioid toxicity deaths were reported nationwide, 97 percent accidental. Males accounted for 72 percent, with the 30-39 age group comprising 26 percent of cases. Stimulant-related harms also decreased, signaling broader reductions in drug toxicity.
Provincially, the picture varies:
- British Columbia: 12 percent decline (2,616 to 2,299 deaths).
- Alberta: 37 percent drop.
- Ontario: 15 percent reduction (2,638 to 2,231).
- Saskatchewan and Manitoba: Modest decreases.
- Quebec: 20 percent rise.
Indigenous communities face rates nearly 10 times the national average, while northern and remote areas, including parts of Ontario, report two to four times higher incidences. These statistics, drawn from coroner reports and emergency data, reflect real-time shifts but caution against complacency.
Researchers at Dalhousie University analyzed Nova Scotia data from 2009 to 2023, noting an early pandemic dip followed by post-2021 rises tied to illicit opioids, emphasizing the role of non-pharmaceutical sources.
Factor 1: Global Supply Shocks Stemming from China’s Crackdown
A pivotal driver is the disruption in the international fentanyl supply chain. Following U.S.-China talks in November 2023, Beijing intensified controls on precursor chemicals, triggering “fentanyl droughts” across North America. Seizure data shows sharp drops in fentanyl amounts by 2024, with Mexican cartels producing less potent variants and Canadian traffickers shifting to analogues.
Jonathan Caulkins, a professor at Carnegie Mellon University, explains that such supply shocks can interrupt epidemic trajectories, akin to Australia’s 2001 heroin shortage that halved deaths. A January 2025 Science journal study corroborates this, linking reduced fentanyl purity to fewer overdoses in Canada and the U.S.
This external pressure has rippled through Canada’s illicit markets, contributing significantly to the opioid deaths decline.
Factor 2: Shifts in Illicit Drug Composition and Reduced Potency
Drug checking services reveal evolving supply dynamics. In Toronto, fentanyl concentrations in samples fell from an average of 5 percent in 2024 to 2 percent in 2025 across 1,300 tests. Benzodiazepine presence also decreased, lowering polysubstance overdose risks. However, new threats like medetomidine—a veterinary sedative 200 times stronger than xylazine—emerged, appearing in 83 percent of January 2025 Toronto samples and 38 percent of British Columbia’s November checks.
Karen McDonald, executive director of Toronto’s Drug Checking Service, notes the volatility: “We’re finding ‘new’ drugs all the time.” The British Columbia Centre on Substance Use (BCCSU), affiliated with the University of British Columbia, reports median fentanyl levels dropping from 20.4 percent to 16.6 percent by April 2025, alongside fewer carfentanil detections (45-87 percent reductions provincially).
These changes suggest a less lethal street supply, though unpredictable adulterants pose ongoing dangers.
Factor 3: Naloxone’s Widespread Proliferation as a Lifesaver
Since Health Canada eliminated naloxone’s prescription requirement in 2016, distribution has tripled from 2020 to 2024. Free kits are now available at pharmacies, harm-reduction sites, schools, construction sites, and even nightclubs in provinces like Ontario and British Columbia. PHAC attributes notable declines in high-distribution areas to this intervention.
Dr. Kit Young Hoon, medical officer at Ontario’s Northwestern Health Unit, credits their province-leading naloxone rates for stabilizing local death rates at triple the provincial average. This opioid antagonist reverses overdoses rapidly via nasal spray or injection, empowering communities and first responders.
PHAC’s tracking dashboard highlights naloxone’s role in curbing fatalities.Factor 4: Transition from Injecting to Smoking Opioids
User behaviors have adapted, with smoking surpassing injecting as the dominant method. This shift allows smaller test doses, reducing overdose risks, and lowers infection rates like endocarditis or osteomyelitis. A January 2025 Addiction journal study led by Dr. George Karandinos of Harvard and Massachusetts General Hospital found smokers die at two-thirds the rate of injectors.
Regional data supports this: increased inhalation-only deaths in Thunder Bay, Ontario, and more smoking in Quebec. PHAC views this as a plausible contributor, reflecting harm-reduction education and supply-driven changes.
Factor 5: Depletion of the Most Vulnerable At-Risk Populations
Tragically, over 53,000 deaths have culled high-risk groups, leaving fewer susceptible individuals. Ontario Chief Coroner Dirk Huyer observes, “Fewer at-risk remain,” with PHAC deeming this a likely factor. Provinces with historically high tolls—like Alberta (over 10,000 lost) and Ontario (over 17,000)—saw the sharpest drops.
Aging demographics among users, fewer youth initiations (e.g., declining diagnoses in B.C.’s 19-24 group), and natural attrition further shrink the pool. University of Waterloo researchers note parallel declines in prescribed opioids since 2017 guidelines, though disparities persist in low-income areas.
Canadian Universities Leading Opioid Decline Research
Higher education institutions are at the forefront. Dalhousie University’s 2025 study on Nova Scotia mortality from 2009-2023 revealed pandemic-era drops followed by illicit opioid surges, guiding targeted interventions. The University of Waterloo’s School of Pharmacy analyzed national prescribing data, finding an 11 percent overall decline but triple rates in poorer neighborhoods—critical for equity-focused policies.
BCCSU at UBC monitors drug checking, informing real-time alerts. These efforts highlight opportunities in public health research; explore research jobs or career advice for academics tackling substance use at AcademicJobs.ca.
Emerging Challenges Despite the Opioid Deaths Decline
Progress is fragile. New adulterants like medetomidine drive localized spikes, and stimulant co-involvement persists. Eastern provinces lag, and inequities burden Indigenous and low-income groups. DJ Larkin of the Canadian Drug Policy Coalition warns, “This is not a moment for celebration.”
Non-fatal harms, hospitalizations, and emergency calls remain high, per CCSA’s 2025 bulletin. Sustaining gains requires addressing root causes like housing, mental health, and treatment access.
CCSA’s Recent Trends Report (PDF) details these nuances.
Policy Implications and the Path Forward
Federal actions emphasize prevention, treatment, and harm reduction. Expanded opioid agonist therapies, supervised consumption sites, and drug checking expand reach. Universities train the next generation of epidemiologists and policymakers.
Ontario Chief Coroner Huyer cautions, “It’s tough to know if it’s going to be sustained.” Balanced approaches—supply disruption, education, and decriminalization discussions—are essential. For professionals, higher ed jobs in public health offer impactful roles.
Photo by Trey Gibson on Unsplash
Looking Ahead: Sustaining Canada’s Opioid Decline
The opioid deaths decline in Canada marks progress but demands action. By leveraging university-led research, scaling harm reduction, and monitoring supply shifts, Canada can build resilience. Stay informed and engaged—visit Rate My Professor for insights into health sciences educators, career advice, or university jobs. Together, we can turn the tide.
